Edgewise Therapeutics, Inc., a biopharmaceutical company that researches treatments for diseases like muscular dystrophy, has hired John Moore as its first general counsel from Peloton Therapeutics Inc.
“I’m excited to join Edgewise at this point in the company’s evolution as we build on the ongoing accomplishments of our innovative research engine to move product candidates into the clinic,” Moore said in an Oct. 29 statement. He officially assumed his new position in September.
Edgewise has hired several executives since June, including Behrad Derakhshan as chief business officer, Michael Carruthers as chief financial officer, Abby Bronson as vice president of patient advocacy and external innovation, and Kirsten Gruis as chief medical officer.
Moore said these additions were needed as the company grows and continues developing its lead product, a muscular dystrophy drug candidate called EDG-5506.
“Getting into the clinic entails a fair amount of extra work that you don’t have when you’re a small startup trying to come up with a drug candidate, and so as the company matures, they needed to bring on additional leadership to help take them to the next phase,” Moore said in an interview.
Moore joins Boulder, Colo.-based Edgewise from Peloton, where he worked as general counsel and secretary for a year. During that time, he led the Dallas-based company’s legal team through IPO preparations and its billion-dollar sale to pharmaceutical company Merck & Co., Inc. Peloton ultimately did not go public due to the merger.
Prior to joining Peloton, Moore ran an independent consulting and legal services company and spent 15 years as vice president and general counsel of Array BioPharma Inc. in Boulder.
Edgewise closed its $50 million series B funding round last September.